Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at USD 92.51 USD in weekly data.
  • The close medium term support offers good timing for purchasing the stock.
  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 49% by 2020.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • With a P/E ratio at 13.42 for the current year and 11.09 for next year, earnings multiples are highly attractive compared with competitors.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • The company's enterprise value to sales, at 4.75 times its current sales, is high.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The technical configuration over the long term remains negative on the weekly chart below the resistance level at 116.78 USD
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
CELGENE CORPORATION-10.03%70 622
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%224 221
PFIZER-1.27%213 155
ROCHE HOLDING LTD.-9.41%207 327
MERCK AND COMPANY-3.06%148 618
AMGEN4.91%132 428
BRISTOL-MYERS SQUIBB COMPAN..8.57%108 890
ABBOTT LABORATORIES3.36%102 678
NOVO NORDISK A/S-4.17%101 783
SANOFI-9.69%100 822
BAYER-5.35%100 123
GLAXOSMITHKLINE-1.47%91 577
ELI LILLY AND COMPANY-8.18%85 390
ASTRAZENECA-6.82%85 057
ALLERGAN PLC-2.61%53 014
More Results
Financials ($)
Sales 2018 14 810 M
EBIT 2018 8 539 M
Net income 2018 5 625 M
Finance 2018 346 M
Yield 2018 -
P/E ratio 2018 13,42
P/E ratio 2019 11,09
EV / Sales 2018 4,75x
EV / Sales 2019 3,82x
Capitalization 70 622 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart CELGENE CORPORATION
Duration : Period : Day
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Duration : Period : Week
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders